no statement of use filed
on 28 Nov 2022
Last Applicant/ Owned by
8700 West Bryn Mawr
Chicago
IL
60631
Serial Number
88893369 filed on 29th Apr 2020
Registration Number
N/A
Correspondent Address
Eric R. Moran
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; house mark for a full line of biologics; house mark for a full line of biosimilars; house mark for a full line of pharmaceuticals; house mark for a full line of biologic, biosimilar, and pharmaceutical products; biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; biologic, biosRead More
house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; house mark for a full line of biologics; house mark for a full line of biosimilars; house mark for a full line of pharmaceuticals; house mark for a full line of biologic, biosimilar, and pharmaceutical products; biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; biologic, biosimilar, and pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders, and complications associated therewith; biologic, biosimilar, and pharmaceutical preparations for the treatment of diabetes; biologic, biosimilar, and pharmaceutical preparations for treatment and prevention of autoimmune diseases and autoimmune disorders; biologic, biosimilar, and pharmaceutical oncology preparations; anti-inflammatories; biologic, biosimilar, and pharmaceutical preparations for the treatment of immune system related diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for use in dermatology; biologic, biosimilar, and pharmaceutical preparations for use in rheumatology; biologic, biosimilar, and pharmaceutical preparations, namely, anti-interleukin-6 (IL-6) receptor monoclonal antibody for the treatment of disease caused by IL-6 production; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders
research and development of biologics, biosimilars, and pharmaceuticals; providing information in the field of scientific and medical research related to biologics, biosimilars, and pharmaceuticals
providing medical information; providing health information
No 88893369
No Service Mark
No MBHB 20-728
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 28th Nov 2022 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| 28th Nov 2022 | ABANDONMENT - NO USE STATEMENT FILED |
| 22nd Apr 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 20th Apr 2022 | SOU EXTENSION 1 GRANTED |
| 20th Apr 2022 | SOU EXTENSION 1 FILED |
| 20th Apr 2022 | TEAS EXTENSION RECEIVED |
| 26th Oct 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 31st Aug 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 31st Aug 2021 | PUBLISHED FOR OPPOSITION |
| 11th Aug 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
